Please login to the form below

Not currently logged in
Email:
Password:

Valeant appoints Howard Schiller to the board

He joins at a time of expansion for the Canadian pharma company

Howard Schiller ValeantValeant Pharmaceuticals has appointed its chief financial officer Howard Schiller to its board of directors.

Schiller has been with Valeant since December 2011, also serving as executive VP in that period.

He joined after retiring from Goldman Sachs, where he was chief operating officer for the investment banking division responsible for the management and strategy of the business.

"Since Howard joined Valeant, his valuable experience and sound counsel have been invaluable to both Valeant's management team and the board of directors," said J Michael Pearson, chair and CEO.

“Appointing him to our board is the next logical step and one I believe will benefit our shareholders."

He joins the board at a time of great expansion for the Canadian pharma company, with several major acquisitions during the past couple of years including gum disease specialists OraPharma, footcare specialist Pedinol and, most recently, a $2.6bn deal to purchase dermatology company Medicis Pharmaceutical.

In addition to his roles at Valeant, Schiller is on the New York board of Teach for America and on the board of the Cancer Research Institute.

24th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics